Circulating Tumor Cell Diagnostics Market is Expected to Reach $14695.6 Million by 2026

ABOUT THIS REPORT

OVERVIEW

Circulating Tumor Cell Diagnostics Market is valued at USD XX million in 2019 and is expected to reach USD 14695.6 million by the end of 2026.

Bizlytikanalysts forecast the global Circulating Tumor Cell Diagnostics market to grow at a CAGR of 16.8% during the forecast period, according to their latest market research report.

In terms of volume, the Circulating Tumor Cell Diagnostics was valued at XX K Units in 2019 and is expected to garner XX K Units by 2026; witnessing a CAGR of 17.3%from 2020 to 2026.

Circulating tumor cell (CTC) is a cell that shed into lymphatics from a primary tumor, carried around the body in the blood circulation. CTCs act as a liquid biopsy to diagnose and monitor cancer. CTC testing has been applied to over 500 clinical trials worldwide. As per studies Circulating tumor cell (CTC) assay, was 84% to 88% accurate at detecting precancerous and cancerous colorectal lesions. FDA has approved blood test for enumerating circulating tumor cells (CTCs). Circulating tumor cells (CTC) Test provides an early assessment of patient prognosis.

Cancer is the second leading cause of death globally. According to World Health Organization (WHO), an estimated 9.6 million deaths in 2018 due to cancer. According to the International Agency for Research on Cancer, the number of cancer cases per year is expected to rise 23.6 million by 2030. According to World Health Organization (WHO), in 2018, around 70% of deaths occur in low- and middle-income countries due to cancer. The most common cancers are Lung cancer with 2.09 million cases, followed by Breast cancer with 2.09 million cases, Colorectal cancer with 1.80 million cases, Prostate cancer with 1.28 million cases, Skin cancer with 1.04 million cases, and Stomach cancer with 1.03 million cases. The rising prevalence of cancer has witnessed continued growth of the market.

CTC Enrichment, CTC Detection, and CTC Analysis are covered in the Type segment of the market scope, while the Application segment is categorized into tumorigenesis Research, EMT Biomarkers Development, Cancer Stem Cell Research, and Others. The report covers value and volume of the global market by Type and Application, with the volume expressed in K Units.

The market value of CTC Enrichment was USD XX Million in 2019, and it is expected to reach USD XX Million by 2026, growing at a CAGR of 16.8% during 2020-2026. The increasing clinical studies on CTC Enrichmentwould propel the growth of the segment.

North America, Europe, AsiaPacific, South America, and Middle East & Africa are taken into consideration at the global Circulating Tumor Cell Diagnostics Volume and Value figures. While North America is further categorized into enhancing United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involvingGCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North AmericaCirculating Tumor Cell Diagnostics market was USD XX Million in 2019, and it is predicted to reach USD XX Million by 2026, growing at a CAGR of XX% during the forecast period. The increasing prevalence of cancer and studies on Circulating Tumor Cell would improve the growth prospects of the market.

Major players operating in the Circulating Tumor Cell Diagnostics industry include Biocept, Epic Scicences, Inc., Fluxion Biosciences, Inc., Greiner Bio-one GmbH, Apocell Inc, CreatvMicrotech, Inc., Ikonisys, Inc., Rarecell Diagnostics, Qiagen Adnagen, Screencell Silicon Biosystems, Advanced Cell Diagnostics (bio-techne).

Screencell Silicon Biosystems is one of the top companies of global Circulating Tumor Cell Diagnostics Market in terms of production volume and value.The increasing R&D activities and extension of business opportunities through strategic partnerships & collaborations are the primarily followed business strategies of top players.